News & Updates

After consulting with pharma industry stakeholders, we’ve seen a strong consensus that in-person interactions are very much needed for business to be done.
While nothing can beat face-to-face interaction whilst doing business, we recognize that in August there may still be some travel restrictions in place. To deliver on our commitment to the North American pharma community, CPhI North America 2021 will be a hybrid event, featuring online components such as a high-level content program as well as smart networking and business matchmaking for those unable to travel to the in-person event. 

Is the pharma industry making the most of AI’s potential when it comes to accelerating and enhancing pharmaceutical drug development? The utilisation of artificial intelligence (AI) by the pharmaceutical industry is gathering pace rapidly. The technology has evolved beyond simple neural networks and machine learning towards a deep learning approach geared at producing insights which should in theory enable better business decision making.

FDA approval of GW Pharmaceuticals’ Epidiolex® is widely considered to be a landmark in cannabinoid-derived drug development. Not only is Epidiolex® the first FDA-approved drug that contains a purified drug substance (cannabidiol) derived from the Cannabis sativa plant (marijuana), but it is also the first FDA approved drug for the treatment of patients with a rare and severe form of childhood epilepsy, Dravet syndrome.

Pipeline diversification, emerging therapies and shifting customer demands are the real dynamics reshaping the contract manufacturing market, according to experts. Almost every article written about contracting reports that demand for outsourced manufacturing services is growing and states that the CDMO sector is consolidating.

Empathy is the ability to understand another person’s feelings and perspectives. By taking the time to relate to others, you build trust,
encourage honesty and open up communication lines. Not only does this create an environment where everyone can fulfil their potential, it also provides far greater scope for innovation.

The biopharma market has enjoyed near exponential growth over the last few decades, which has boosted total revenues by over 6,000% from USD 4 billion since the 1990s to $275 billion today. With biopharmaceuticals now comprising 25% of the total pharma market, the pressure is on to maintain this growth and innovation.

As the pharmaceutical industry tirelessly seeks to accelerate its medicines to market, drug manufacturing remains a key opportunity area for it to reduce costs and  improve quality. The technology advances promised from Pharma 4.0  -- such as big data, interconnectivity, robotics and artificial intelligence -- and smart manufacturing techniques have given business leaders greater visibility into their pipelines and processes.

The biopharmaceutical industry is at a crossroads when it comes to drug development. On the one hand, this time-intensive process of navigating a molecule successfully through the preclinical and clinical stages all the way to market has been saddled with high capital costs and stringent regulation; two factors that justify both a risk-averse approach and an urge to rein in R&D expenses.

With CPhI North America fast approaching, we asked several industry experts what they see as the main trends emerging across the US pharma supply chain this year.

It would be disingenuous to claim 2019 was a revolutionary year for pharma as it continues its journey towards a patient-centric model.

As biopharma heads towards a new decade, extracting value from innovation remains a key theme in medicines development. 

Players in the pharmaceutical value chain will need to fully harness cutting-edge digital technologies such as artificial intelligence (AI) and cyber-security solutions to make greater efficiency...